Future studies may prove targeting GR and/or NECAB1 in β-cells as a novel therapeutic approach for obesity-related diabetes mellitus, which has become a worldwide pandemic. This evidence concerns the gene NR3C1 and obesity due to melanocortin 4 receptor deficiency.